Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Landiolol for Prevention of Postoperative Atrial Fibrillation After Cardiac Surgery
NCT04607122Phase 3Completed
- Sponsor
- CMC Ambroise Paré
- Start
- Jan 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Landiolol group with Placebo group (2 arms). Primary endpoint: Postoperative Atrial Fibrillation occurrence in Intensive Care Unit (ICU) at 7 days. Started Jan 2021; status: completed.
02
Drugs
landiolol
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04607122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607122.